Major findings of the current study can be summarized as follows: (i) UA levels were higher in women with pre-gestational overweight/obesity, in the high-risk group (as defined earlier), and in those who required insulin therapy; (ii) UA levels were positively correlated with BMI and glycemia both during pregnancy and postpartum; (iii) gestational age at delivery was negatively correlated with UA levels postpartum; and (iv) the genetic component for UA levels was confirmed for rs1014290, rs12498742, rs734553, and rs16890979 in GLUT9 (encoded by the SLC2A9 gene). The gene discussed is SLC2A9; the disease is obesity due to melanocortin 4 receptor deficiency.